These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38745749)

  • 21. Intralesional administration of VAX014 facilitates in situ immunization and potentiates immune checkpoint blockade in immunologically cold tumors.
    Reil KA; Tsuji S; Molina E; Nelson KL; McGuire KL; Giacalone MJ
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37290924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer.
    Mostafa AA; Meyers DE; Thirukkumaran CM; Liu PJ; Gratton K; Spurrell J; Shi Q; Thakur S; Morris DG
    Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29914097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H.
    Hazini A; Dieringer B; Klingel K; Pryshliak M; Geisler A; Kobelt D; Daberkow O; Kurreck J; Linthout SV; Fechner H
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome.
    Sam M; Selman M; Zhao W; Jung J; Willingham A; Phan U; Starling GC; Gao Q
    J Virol; 2023 May; 97(5):e0030923. PubMed ID: 37070982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncolytic Adenovirus ORCA-010 Activates Proinflammatory Myeloid Cells and Facilitates T Cell Recruitment and Activation by PD-1 Blockade in Melanoma.
    Milenova I; Lopez Gonzalez M; Quixabeira DCA; Santos JM; Cervera-Carrascon V; Dong W; Hemminki A; van Beusechem VW; van de Ven R; de Gruijl TD
    Hum Gene Ther; 2021 Feb; 32(3-4):178-191. PubMed ID: 33470166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21.
    Au GG; Lindberg AM; Barry RD; Shafren DR
    Int J Oncol; 2005 Jun; 26(6):1471-6. PubMed ID: 15870858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of anti-PD-1 monotherapy
    Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
    Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab.
    Truong P; Rahal A; Kallail KJ
    Cureus; 2016 Jun; 8(6):e631. PubMed ID: 27433410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A physiologically based pharmacokinetic model for V937 oncolytic virus in mice.
    Peribañez-Dominguez S; Parra-Guillen ZP; Freshwater T; Troconiz IF
    Front Pharmacol; 2023; 14():1211452. PubMed ID: 37771727
    [No Abstract]   [Full Text] [Related]  

  • 31. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
    Niu J; Maurice-Dror C; Lee DH; Kim DW; Nagrial A; Voskoboynik M; Chung HC; Mileham K; Vaishampayan U; Rasco D; Golan T; Bauer TM; Jimeno A; Chung V; Chartash E; Lala M; Chen Q; Healy JA; Ahn MJ
    Ann Oncol; 2022 Feb; 33(2):169-180. PubMed ID: 34800678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of the intercellular adhesion molecule (ICAM-1) on squamous cell carcinoma by interferon gamma.
    Scher RL; Koch WM; Richtsmeier WJ
    Arch Otolaryngol Head Neck Surg; 1993 Apr; 119(4):432-8. PubMed ID: 8096142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.
    Ribas A; Medina T; Kummar S; Amin A; Kalbasi A; Drabick JJ; Barve M; Daniels GA; Wong DJ; Schmidt EV; Candia AF; Coffman RL; Leung ACF; Janssen RS
    Cancer Discov; 2018 Oct; 8(10):1250-1257. PubMed ID: 30154193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory.
    Veinalde R; Pidelaserra-Martí G; Moulin C; Jeworowski LM; Küther L; Buchholz CJ; Jäger D; Ungerechts G; Engeland CE
    Mol Ther Oncolytics; 2022 Mar; 24():43-58. PubMed ID: 34977341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1.
    Zhu Y; Hu X; Feng L; Yang Z; Zhou L; Duan X; Cheng S; Zhang W; Liu B; Zhang K
    Mol Ther Oncolytics; 2019 Dec; 15():201-213. PubMed ID: 31788554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
    Ribas A; Dummer R; Puzanov I; VanderWalde A; Andtbacka RHI; Michielin O; Olszanski AJ; Malvehy J; Cebon J; Fernandez E; Kirkwood JM; Gajewski TF; Chen L; Gorski KS; Anderson AA; Diede SJ; Lassman ME; Gansert J; Hodi FS; Long GV
    Cell; 2017 Sep; 170(6):1109-1119.e10. PubMed ID: 28886381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer Using Oxaliplatin and Coxsackievirus A11.
    Wang B; Ogata H; Takishima Y; Miyamoto S; Inoue H; Kuroda M; Yamada K; Hijikata Y; Murahashi M; Shimizu H; Okazaki T; Nakanishi Y; Tani K
    Anticancer Res; 2018 Nov; 38(11):6121-6126. PubMed ID: 30396927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent oncolytic activity of human enteroviruses against human prostate cancer.
    Berry LJ; Au GG; Barry RD; Shafren DR
    Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.